MedPath

Prediction of the pharmacokinetics and adverse events of nab-paclitaxel in patients with pancreatic cancer by magnetic resonance imaging

Not Applicable
Recruiting
Conditions
nresectable locally advanced pancreatic cancer or metastatic pancreatic cancer
Registration Number
JPRN-UMIN000026180
Lead Sponsor
Juntendo University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1. Hypersensitivity to Gd-EOB-DTPA

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The relationship between the pretreatment parenchymal hepatic enhancement effect of Gd-EOB-DTPA MRI and the plasma paclitaxel concentration.
Secondary Outcome Measures
NameTimeMethod
The relationship among enhancement effect of Gd-EOB-DTPA, development of peripheral neuropathy during chemotherapy, and gene polymorphisms of hepatic transporter
© Copyright 2025. All Rights Reserved by MedPath